NEW YORK--()--SeeThruEquity, a leading investment research and corporate access firm focused on public smallcap and microcap companies, is hosting its Smallcap and Microcap Investor Summit on December 4th, 2012 at the Cornell Club in midtown Manhattan. Registration will begin at 8:00am and the conference will run from 9:30am to 5pm. The first presentation will begin at 9:30am.
Senior management from a select group of companies will make presentations about their respective businesses to an elite group of institutional and retail investors, equity analysts and industry professionals. 1-on-1 meetings between qualified investors and the presenting companies will also be arranged by appointment.
The schedule for the conference is as follows:
Breakfast, Networking and Registration
|9:20-9:30 am||Opening Remarks|
|9:30-10:10 am||Stellar Pharmaceuticals (OTCBB: SLXCF)|
|10:10-10:50 am||Glowpoint, Inc. (NYSE: GLOW)|
|10:50-11:05 am||Networking Break|
|11:05-11:45 am||Boston Therapeutics, Inc. (OTCBB: BTHE)|
|1:00-1:40 pm||iCo Therapeutics, Inc. (TSXV: ICO.V)|
|1:40-2:20 pm||DecisionPoint Systems, Inc. (OTCBB: DPSI)|
|2:20-2:35 pm||Networking Break|
|2:35-3:15 pm||Eastbridge Investment Group Corporation (OTCBB: EBIG)|
|3:15-3:55 pm||ChatAnd Inc.|
|4:00-5:00 pm||Networking Cocktail Hour|
Investors and equity research analysts may attend the conference without charge and other interested parties may join the conference for a $149 fee. Please visit SeeThruEquity Smallcap and Microcap Summit Home Page for more information about the conference.
You may register for the conference at: SeeThruEquity Smallcap and Microcap Summit Attendee Registration.
About SeeThruEquity, LLC
SeeThruEquity, LLC is an investment research and corporate access firm that produces high quality research reports on smallcap and microcap companies with less than $1 billion in market capitalization. The traditional Wall Street analyst establishment has typically underserved these companies. We are unfettered by any ties to investment banking or trading, and distribute our high impact research as an approved firm for consensus estimates on Thomson Reuters, CapitalIQ, FactSet, Zacks and StockTwits, as well as to our own audience of investors from our corporate website.
Our philosophy is focused on delivering an unbiased, institutional quality research product for such uncovered or undercovered companies to all levels of investors in the investment community and at absolutely no charge to the reader of the research or the company being covered. We seek to build relationships between corporate issuers and institutional and sophisticated investors via compelling investor conferences and forums as well as non-deal road shows.